Oxford, UK – Vaccitech announces today that its scientific founders at the Jenner Institute, University of Oxford, have begun testing a COVID-19 vaccine in human volunteers. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine. The vaccine, jointly designed by Vaccitech and University of Oxford, comprises Vaccitech’s ChAdOx1 adenovirus vaccine vector platform encoding the spike protein of SARS-CoV-2, the COVID-19 virus.
The University of Oxford started screening healthy volunteers (aged 18-55) in March for their trial and have now vaccinated the first participants. The trial aims to assess whether the new vaccine, ChAdOx1 nCoV-19, can protect healthy people from COVID-19. It will also provide valuable information on safety aspects of the vaccine and its ability to generate good immune responses against the virus.